Revenue Recognition (Details) $ / shares in Units, $ in Thousands	1 Months Ended			3 Months Ended			9 Months Ended
	Mar. 31, 2023 USD ($) item	Aug. 31, 2019	Feb. 28, 2019 USD ($)	Sep. 30, 2024 USD ($) $ / shares	Sep. 30, 2023 USD ($) $ / shares	Jun. 30, 2023 USD ($)	Sep. 30, 2024 USD ($) $ / shares	Sep. 30, 2023 USD ($) $ / shares	Dec. 31, 2023 USD ($)	Dec. 31, 2022 USD ($)	Jun. 30, 2019 USD ($)
Allowances on accounts receivable									$ 1,300
Other assets				$ 38,356			$ 38,356		15,403
Deferred revenue				34,802	$ 36,045		34,802	$ 36,045	35,740	$ 30,778
Disruption at Change Healthcare
Allowances on accounts receivable				26,900			$ 26,900
Product
Approximate percentage of revenue collected within 9 months							90.00%
Billing collection period (in months)							9 months
Extended billing collection period (in months)							6 months
Increased (decreased) revenues				700	1,200		$ 4,500	7,700
(Increased) decreased net loss				$ 700	$ 1,200		$ 4,500	$ 7,700
(Increased) decreased net loss per share | $ / shares				$ 0.01	$ 0.01		$ 0.04	$ 0.07
Tests delivered in prior periods that were fully collected
Increased (decreased) revenues				$ 34,500	$ 2,200		$ 108,100	$ (3,700)
(Increased) decreased net loss				$ 34,500	$ 2,200		$ 108,100	$ (3,700)
(Increased) decreased net loss per share | $ / shares				$ 0.28	$ 0.02		$ 0.88	$ (0.03)
Tests delivered in prior periods that were fully collected | Disruption at Change Healthcare
Allowances on accounts receivable				$ 2,500			$ 2,500
Amounts not refunded to insurance carriers
Increased (decreased) revenues				2,900			7,100
(Increased) decreased net loss				$ 2,900			$ 7,100
(Increased) decreased net loss per share | $ / shares				$ 0.02			$ 0.06
BGI Genomics
Revenue recognized			$ 44,000
Agreement term			10 years
Revenue, remaining performance obligation			$ 6,000
Transaction price			50,000
Contract asset				$ 1,000			$ 1,000
Other assets				3,400			3,400
Deferred revenue				17,400			17,400
Prepaid royalties			$ 20,000
BGI Genomics | License and related development services
Number of performance obligations | item	2
Revenue, remaining performance obligation	$ 24,000
BGI Genomics | Sequencing services
Other assets											$ 6,000
BGI Genomics | Sequencing products
Other assets											4,000
BGI Genomics | Sequencing products and services
Other assets											$ 10,000
BGI Genomics | Oncology assay interpretation services
Revenue recognized							1,500	$ 1,100
Revenue, remaining performance obligation									$ 20,000
Deferred revenue				1,400	$ 700		1,400	700
BGI Genomics | Equipment and Services
Equipment and services received				400	1,400		400	4,000
Foundation Medicine ("FMI")
Revenue recognized							24,300
Agreement term		5 years
Automatic renewals, successive period thereafter		1 year
Revenue, remaining performance obligation				7,700			7,700
Transaction price				32,000			32,000
Prepaid royalties				5,000			5,000
Foundation Medicine ("FMI") | Oncology assay interpretation services
Revenue recognized				100	$ (100)		300	$ 300
Revenue, remaining performance obligation				5,000			5,000
Deferred revenue				$ 3,000			$ 3,000
Foundation Medicine ("FMI") | Oncology products
Revenue recognized						$ 200
Revenue, remaining performance obligation						$ 19,300